Babu J. Mavunkel

TL;DR: In this paper, the authors present methods to treat conditions mediated by kinase using compounds of formula (1) and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein Z is N or CR1, R1 is a noninterfering substituent, each of X?1 and X2? is a linker, Ar?1 or Ar2? are identical or different, and represent optionally substituted C1-C20 hydrocarbyl residues.

TL;DR: In this paper, the authors define the pharmaceutically acceptable compounds of formula (I), (υ) wherein the dotted line represents an optional bond; and the pharmacologically acceptable salts thereof, wherein X1 is an alkyl bridge optionally containing an O, S, or N heteroatom that forms an aliphatic 5-7 membered ring and is optionally substituted by one or more of halo, OR, SR, NR?2?, RCO, COOR, CONR2, OOCR, or NROCR.

TL;DR: In this paper, a method to inhibit p38-α kinase using compounds comprising a phenyl or thienyl coupled through a piperidine or piperazine nucleus to an indole residue was proposed.

TL;DR: The novel pseudopeptide bradykinin B2 receptor antagonist, NPC 18521, has an effect with rapid onset, and produces potent and relatively long-lasting antioedematogenic and antinociceptive properties.

TL;DR: In this article, the authors describe methods to treat conditions mediated by p38-alphakinase using compounds of the formula and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, where Z is N or CR1, R1 is a noninterfering substituent, each of X1 and X2 is a linker, Ar1 and Ar2 are identical or different, and represent optionally substituted C1-C20 hydrocarbyl residues.